Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Thalidomide may stop the growth of non-small cell lung cancer by blocking blood flow to the
tumor. Thalidomide may also help docetaxel work better by making tumor cells more sensitive
to the drug. Giving docetaxel together with thalidomide may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel together with thalidomide
works as second-line therapy in treating patients with stage III or stage IV non-small cell
lung cancer.